Welcome to our dedicated page for LENZ THERAPEUTICS news (Ticker: LENZ), a resource for investors and traders seeking the latest updates and insights on LENZ THERAPEUTICS stock.
LENZ Therapeutics, Inc. (Nasdaq: LENZ) is a pharmaceutical company headquartered in San Diego, California, focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, which it describes as the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. The LENZ news feed highlights regulatory milestones, commercial launch updates, licensing agreements and medical community engagement related to this presbyopia therapy.
Visitors to this page can follow company announcements on topics such as FDA approval of VIZZ, the start of professional sample distribution to optometrists and ophthalmologists, and the rollout of commercial product availability through ePharmacy channels and retail pharmacies in the United States. LENZ also issues news about early launch metrics, including the number of eye care professionals prescribing VIZZ and prescription volumes in its initial quarters on the market.
Because LENZ is focused on a single branded product, its news often centers on presbyopia treatment, clinical data from the CLARITY Phase 3 trials, and safety and tolerability information for VIZZ. The company also reports on its participation in investor and medical conferences, where management discusses commercial progress and clinicians present data on aceclidine 1.44% ophthalmic solution and optimal pupil size for miotic treatment of presbyopia.
International expansion is another recurring theme in LENZ news. Press releases describe exclusive commercialization partnerships for VIZZ in the Middle East with Lunatus, a licensing and commercialization agreement with Lotus Pharmaceutical in South Korea and Southeast Asia, and other regional arrangements. Updates on direct-to-consumer initiatives, such as the “Make it VIZZable” campaign featuring Sarah Jessica Parker as brand ambassador, provide additional context on how LENZ is promoting VIZZ to adults living with age-related blurry near vision.
LENZ Therapeutics (Nasdaq: LENZ) will report third quarter 2025 financial results and recent corporate highlights on Wednesday, November 5, 2025 at 8:30 a.m. EST via live webcast and conference call.
The company is a pharmaceutical firm commercializing VIZZ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine eye drop for presbyopia in adults. Participants may join by phone (Domestic: (800) 715-9871; International: (646) 307-1963) using access code 1685282. The live webcast is available on LENZ Therapeutics’ investor website and a replay will be posted for 30 days after the event.
LENZ Therapeutics (NASDAQ:LENZ) has announced the commercial availability of VIZZ™, their FDA-approved aceclidine-based eye drop treatment for presbyopia in adults. The product is being distributed as samples to eye care professionals nationwide, with commercial shipments starting in October through their ePharmacy partner.
VIZZ is notable as the first and only aceclidine-based eye drop approved for presbyopia, targeting a market of approximately 128 million adults in the United States. The treatment works through a pupil-selective miotic mechanism, achieving sub-2mm pupil size to improve near vision for up to 10 hours. Clinical trials showed 93% of participants achieved 20/40 or better near vision within 30 minutes.
LENZ Therapeutics (NASDAQ: LENZ), developer of VIZZ™ (aceclidine ophthalmologic solution) 1.44% for presbyopia treatment, announced its participation in multiple upcoming investor and medical conferences in September and October 2025.
The company will present at four major investor conferences: Citi's BioPharma Back to School Conference, Cantor Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and Morgan Stanley Global Healthcare Conference. All presentations will include live audio webcasts available on LENZ's website.
Additionally, at Academy 2025 Boston, two presentations will feature VIZZ: an oral podium presentation on efficacy and performance measures, and a poster presentation on optimal pupil size for miotic treatment of presbyopia.
LENZ Therapeutics (NASDAQ:LENZ) has received FDA approval for VIZZ™ (aceclidine ophthalmic solution 1.44%), the first and only aceclidine-based eye drop for treating presbyopia in adults. The product represents a breakthrough as the first once-daily solution providing up to 10 hours of improved near vision.
VIZZ works through a unique mechanism of action, contracting the iris sphincter muscle to achieve a sub-2mm pupil without causing myopic shift. The approval was supported by three Phase 3 studies (CLARITY 1, 2, and 3) involving 683 participants, demonstrating consistent efficacy within 30 minutes of application and good tolerability with no serious treatment-related adverse events.
Commercial launch is expected by mid-Q4 2025, with samples available as early as October 2025. The product addresses a significant market of approximately 128 million adults in the United States affected by presbyopia.
LENZ Therapeutics (NASDAQ:LENZ) reported Q2 2025 financial results and significant milestones in their presbyopia treatment program. The company's lead drug candidate LNZ100 has a PDUFA date of August 8, 2025, with FDA review progressing smoothly. LENZ has secured multiple international licensing deals worth over $195 million in potential payments plus double-digit royalties.
The company has completed hiring an 88-member sales force ready for immediate post-approval launch. Financial position remains strong with $209.6 million in cash as of June 30, 2025. Q2 net loss was $14.9 million ($0.53 per share), compared to $10.3 million ($0.40 per share) in Q2 2024.
LENZ Therapeutics (NASDAQ:LENZ) announced that its partner CORXEL Pharmaceuticals has submitted a New Drug Application (NDA) for LNZ100 to China's NMPA for presbyopia treatment. The submission is supported by successful Phase 3 JX07001 clinical trial results, where LNZ100 achieved its primary and secondary endpoints.
The NDA submission triggers the first milestone payment under the April 2022 licensing agreement, under which LENZ is eligible to receive up to $95.0 million in regulatory and sales milestones, plus tiered mid single-digit to low double-digit royalties on Greater China net sales.
LENZ Therapeutics (NASDAQ:LENZ) has entered into an exclusive license and commercialization agreement with Laboratoires Théa for LNZ100, a presbyopia treatment, in Canada. The deal includes over $70 million in upfront and milestone payments, plus double-digit royalties on net sales.
LNZ100, the first and only aceclidine-based eye drop for presbyopia, has a FDA PDUFA date of August 8, 2025. The FDA accepted the NDA in October 2024 and does not plan to hold an Advisory Committee Meeting. The treatment targets a condition affecting 1.8 billion people globally, including 128 million in the United States.
LENZ Therapeutics (NASDAQ: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, has announced its participation in three major upcoming investor conferences in June 2025:
- William Blair Growth Stock Conference on June 3 in Chicago (presentation at 1:40pm EDT)
- Jefferies Global Healthcare Conference on June 4-5 in New York City (presentation at 9:55am EDT)
- Goldman Sachs Global Healthcare Conference on June 9 in Miami Beach (fireside chat at 4:00pm EDT)
Live webcasts for the Jefferies and Goldman Sachs presentations will be available on LENZ's website, with replays accessible for 12 months. The company will also conduct one-on-one investor meetings at all three conferences.
LENZ Therapeutics (NASDAQ: LENZ) has entered into an exclusive license and commercialization agreement with Lotus Pharmaceutical for LNZ100, a presbyopia treatment eye drop, in Korea and Southeast Asia. The deal includes up to $125 million in upfront and milestone payments, plus double-digit royalties on future sales.
Lotus will have exclusive rights for LNZ100 in Korea, Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia, and Singapore. The agreement targets a market of over 100 million people affected by presbyopia in these regions. The FDA has already accepted LENZ's NDA for LNZ100 with a PDUFA date of August 8, 2025.